LINC00891 Promotes Tumorigenesis and Metastasis of Thyroid Cancer by Regulating SMAD2/3 via EZH2


Дәйексөз келтіру

Толық мәтін

Аннотация

Background:Thyroid cancer (TC), the most common endocrine malignant tumor, is increasingly causing a huge threat to our health nowadays.

Methods:To explore the tumorigenesis mechanism of thyroid cancer, we identified that long intergenic non-coding RNA-00891 (LINC00891) was upregulated in TC using the Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and local databases. LINC00891 expression was correlated with histological type and lymph node metastasis (LNM). The high expression of LINC00891 could serve as a diagnostic marker for TC and its LNM. In vitro experiments demonstrated that LINC00891 knockdown could inhibit cell proliferation, migration, invasion and prompt apoptosis and G1 arrest of TC cells. We also investigated the related mechanisms of LINC00891 promoting TC progression using RNA sequencing, Gene Set Enrichment Analysis, and Western blotting.

Results:Our experiments demonstrated that LINC00891 promoted TC progression via the EZH2-SMAD2/3 signaling axis. In addition, overexpression of EZH2 could reverse the suppressive epithelial-to-mesenchymal transition (EMT) caused by LINC00891 knockdown.

Conclusion:In conclusion, the LINC00891/EZH2/SMAD2/3 regulatory axis participated in tumorigenesis and metastasis of thyroid cancer, which may provide a novel target for treatment.

Авторлар туралы

Yuhao Si

Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University

Email: info@benthamscience.net

Jialiang Wen

Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine

Email: info@benthamscience.net

Chunlei Hu

Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University

Email: info@benthamscience.net

Hao Chen

Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical UniversityMedical University

Email: info@benthamscience.net

Lizhi Lin

Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University

Email: info@benthamscience.net

Yiying Xu

Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University

Email: info@benthamscience.net

Disuo Ren

Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University

Email: info@benthamscience.net

Xinyu Meng

Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University

Email: info@benthamscience.net

Yinghao Wang

Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University

Email: info@benthamscience.net

Erjie Xia

Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University

Email: info@benthamscience.net

Adheesh Bhandari

Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University

Хат алмасуға жауапты Автор.
Email: info@benthamscience.net

Ouchen Wang

Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University

Хат алмасуға жауапты Автор.
Email: info@benthamscience.net

Әдебиет тізімі

  1. Trigo, J.M.; Capdevila, J.; Grande, E.; Grau, J.; Lianes, P. Thyroid cancer: SEOM clinical guidelines. Clin. Transl. Oncol., 2014, 16(12), 1035-1042. doi: 10.1007/s12094-014-1224-4 PMID: 25245079
  2. Li, M.; Maso, L.D.; Vaccarella, S. Global trends in thyroid cancer incidence and the impact of overdiagnosis. Lancet Diabetes Endocrinol., 2020, 8(6), 468-470. doi: 10.1016/S2213-8587(20)30115-7 PMID: 32445733
  3. Miranda-Filho, A.; Lortet-Tieulent, J.; Bray, F.; Cao, B.; Franceschi, S.; Vaccarella, S.; Dal Maso, L. Thyroid cancer incidence trends by histology in 25 countries: A population-based study. Lancet Diabetes Endocrinol., 2021, 9(4), 225-234. doi: 10.1016/S2213-8587(21)00027-9 PMID: 33662333
  4. Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer statistics, 2021. CA Cancer J. Clin., 2021, 71(1), 7-33. doi: 10.3322/caac.21654 PMID: 33433946
  5. Zhang, S.; Sun, K.; Zheng, R.; Zeng, H.; Wang, S.; Chen, R.; Wei, W.; He, J. Cancer incidence and mortality in China, 2015. J. Natl. Cancer Inst., 2021, 1(1), 2-11. doi: 10.1016/j.jncc.2020.12.001
  6. Mirian, C.; Grønhøj, C.; Jensen, D.H.; Jakobsen, K.K.; Karnov, K.; Jensen, J.S.; Hahn, C.H.; Klitmøller, T.A.; Bentzen, J.; von Buchwald, C. Trends in thyroid cancer: Retrospective analysis of incidence and survival in Denmark 1980–2014. Cancer Epidemiol., 2018, 55, 81-87. doi: 10.1016/j.canep.2018.05.009 PMID: 29852396
  7. Shaha, A. Treatment of thyroid cancer based on risk groups. J. Surg. Oncol., 2006, 94(8), 683-691. doi: 10.1002/jso.20697 PMID: 17131422
  8. Sampson, E.; Brierley, J.D.; Le, L.W.; Rotstein, L.; Tsang, R.W. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer, 2007, 110(7), 1451-1456. doi: 10.1002/cncr.22956 PMID: 17705176
  9. Marchese, F.P.; Raimondi, I.; Huarte, M. The multidimensional mechanisms of long noncoding RNA function. Genome Biol., 2017, 18(1), 206. doi: 10.1186/s13059-017-1348-2 PMID: 29084573
  10. Kang, W.; Wang, Q.; Dai, Y.; Wang, H.; Wang, M.; Wang, J.; Zhang, D.; Sun, P.; Qi, T.; Jin, X.; Cui, Z. Hypomethylation of PlncRNA-1 promoter enhances bladder cancer progression through the miR-136-5p/Smad3 axis. Cell Death Dis., 2020, 11(12), 1038. doi: 10.1038/s41419-020-03240-z PMID: 33288752
  11. Chang, K.C.; Diermeier, S.D.; Yu, A.T.; Brine, L.D.; Russo, S.; Bhatia, S.; Alsudani, H.; Kostroff, K.; Bhuiya, T.; Brogi, E.; Pappin, D.J.; Bennett, C.F.; Rigo, F.; Spector, D.L. MaTAR25 lncRNA regulates the Tensin1 gene to impact breast cancer progression. Nat. Commun., 2020, 11(1), 6438. doi: 10.1038/s41467-020-20207-y PMID: 33353933
  12. Cai, H.; Yu, Y.; Ni, X.; Li, C.; Hu, Y.; Wang, J.; Chen, F.; Xi, S.; Chen, Z. LncRNA LINC00998 inhibits the malignant glioma phenotype via the CBX3-mediated c-Met/Akt/mTOR axis. Cell Death Dis., 2020, 11(12), 1032. doi: 10.1038/s41419-020-03247-6 PMID: 33268783
  13. Guo, K.; Qian, K.; Shi, Y.; Sun, T.; Wang, Z. LncRNA-MIAT promotes thyroid cancer progression and function as ceRNA to target EZH2 by sponging miR-150-5p. Cell Death Dis., 2021, 12(12), 1097. doi: 10.1038/s41419-021-04386-0 PMID: 34811354
  14. Ye, M.; Dong, S.; Hou, H.; Zhang, T.; Shen, M. Oncogenic role of long noncoding RNAMALAT1 in thyroid cancer progression through regulation of the miR-204/IGF2BP2/m6A-MYC signaling. Mol. Ther. Nucleic Acids, 2021, 23, 1-12. doi: 10.1016/j.omtn.2020.09.023 PMID: 33312756
  15. Chen, B.J.; Byrne, F.L.; Takenaka, K.; Modesitt, S.C.; Olzomer, E.M.; Mills, J.D.; Farrell, R.; Hoehn, K.L.; Janitz, M. Transcriptome landscape of long intergenic non-coding RNAs in endometrial cancer. Gynecol. Oncol., 2017, 147(3), 654-662. doi: 10.1016/j.ygyno.2017.10.006 PMID: 29050779
  16. Ma, X.; Li, Y.; Song, Y.; Xu, G. Long noncoding RNA CCDC26 promotes thyroid cancer malignant progression via miR-422a/EZH2/Sirt6 Axis. OncoTargets Ther., 2021, 14, 3083-3094. doi: 10.2147/OTT.S282011 PMID: 34007185
  17. Wang, L.J.; Sun, G.Z.; Chen, Y.F. LncRNA MSTO2P promotes proliferation and autophagy of lung cancer cells by up-regulating EZH2 expression. Eur. Rev. Med. Pharmacol. Sci., 2019, 23(8), 3375-3382. doi: 10.26355/eurrev_201904_17701 PMID: 31081092
  18. Xu, M.; Chen, X.; Lin, K.; Zeng, K.; Liu, X.; Xu, X.; Pan, B.; Xu, T.; Sun, L.; He, B.; Pan, Y.; Sun, H.; Wang, S. lncRNA SNHG6 regulates EZH2 expression by sponging miR-26a/b and miR-214 in colorectal cancer. J. Hematol. Oncol., 2019, 12(1), 3. doi: 10.1186/s13045-018-0690-5 PMID: 30626446
  19. Wu, Y.; Hu, L.; Liang, Y.; Li, J.; Wang, K.; Chen, X.; Meng, H.; Guan, X.; Yang, K.; Bai, Y. Up-regulation of lncRNA CASC9 promotes esophageal squamous cell carcinoma growth by negatively regulating PDCD4 expression through EZH2. Mol. Cancer, 2017, 16(1), 150. doi: 10.1186/s12943-017-0715-7 PMID: 28854977
  20. Barros-Filho, M.C.; de Mello, J.B.H.; Marchi, F.A.; Pinto, C.A.L.; da Silva, I.C.; Damasceno, P.K.F.; Soares, M.B.P.; Kowalski, L.P.; Rogatto, S.R. GADD45B transcript is a prognostic marker in papillary thyroid carcinoma patients treated with total thyroidectomy and radioiodine therapy. Front. Endocrinol., 2020, 11, 269. doi: 10.3389/fendo.2020.00269 PMID: 32425887
  21. Barros-Filho, M.C.; Marchi, F.A.; Pinto, C.A.; Rogatto, S.R.; Kowalski, L.P. High diagnostic accuracy based on CLDN10, HMGA2, and LAMB3 transcripts in papillary thyroid carcinoma. J. Clin. Endocrinol. Metab., 2015, 100(6), E890-E899. doi: 10.1210/jc.2014-4053 PMID: 25867809
  22. Jiang, H.; Wong, W.H. SeqMap: Mapping massive amount of oligonucleotides to the genome. Bioinformatics, 2008, 24(20), 2395-2396. doi: 10.1093/bioinformatics/btn429 PMID: 18697769
  23. Troyanskaya, O.; Cantor, M.; Sherlock, G.; Brown, P.; Hastie, T.; Tibshirani, R.; Botstein, D.; Altman, R.B. Missing value estimation methods for DNA microarrays. Bioinformatics, 2001, 17(6), 520-525. doi: 10.1093/bioinformatics/17.6.520 PMID: 11395428
  24. Subramanian, A.; Tamayo, P.; Mootha, V.K.; Mukherjee, S.; Ebert, B.L.; Gillette, M.A.; Paulovich, A.; Pomeroy, S.L.; Golub, T.R.; Lander, E.S.; Mesirov, J.P. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA, 2005, 102(43), 15545-15550. doi: 10.1073/pnas.0506580102 PMID: 16199517
  25. Tang, Z.; Li, C.; Kang, B.; Gao, G.; Li, C.; Zhang, Z. GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res., 2017, 45(W1), W98-W102. doi: 10.1093/nar/gkx247 PMID: 28407145
  26. Wu, N.; Jiang, M.; Liu, H.; Chu, Y.; Wang, D.; Cao, J.; Wang, Z.; Xie, X.; Han, Y.; Xu, B. LINC00941 promotes CRC metastasis through preventing SMAD4 protein degradation and activating the TGF-β/SMAD2/3 signaling pathway. Cell Death Differ., 2021, 28(1), 219-232. doi: 10.1038/s41418-020-0596-y PMID: 32737443
  27. Li, H.; Zhang, Z.; Chen, L.; Sun, X.; Zhao, Y.; Guo, Q.; Zhu, S.; Li, P.; Min, L.; Zhang, S. Cytoplasmic Asporin promotes cell migration by regulating TGF-β/Smad2/3 pathway and indicates a poor prognosis in colorectal cancer. Cell Death Dis., 2019, 10(2), 109. doi: 10.1038/s41419-019-1376-9 PMID: 30728352
  28. Zhang, B.; Ye, H.; Ren, X.; Zheng, S.; Zhou, Q.; Chen, C.; Lin, Q.; Li, G.; Wei, L.; Fu, Z.; Zhang, Y.; Hu, C.; Li, Z.; Chen, R. Macrophage-expressed CD51 promotes cancer stem cell properties via the TGF-β1/smad2/3 axis in pancreatic cancer. Cancer Lett., 2019, 459, 204-215. doi: 10.1016/j.canlet.2019.06.005 PMID: 31199988
  29. Zhong, F.J.; Sun, B.; Cao, M.M.; Xu, C.; Li, Y.M.; Yang, L.Y. STMN2 mediates nuclear translocation of Smad2/3 and enhances TGFβ signaling by destabilizing microtubules to promote epithelial-mesenchymal transition in hepatocellular carcinoma. Cancer Lett., 2021, 506, 128-141. doi: 10.1016/j.canlet.2021.03.001 PMID: 33705863
  30. Duan, R.; Du, W.; Guo, W. EZH2: A novel target for cancer treatment. J. Hematol. Oncol., 2020, 13(1), 104. doi: 10.1186/s13045-020-00937-8 PMID: 32723346
  31. Zhang, Y.; Song, D.; Peng, Z.; Wang, R.; Li, K.; Ren, H.; Sun, X.; Du, N.; Tang, S.C. LINC00891 regulated by miR-128-3p/GATA2 axis impedes lung cancer cell proliferation, invasion and EMT by inhibiting RhoA pathway. Acta Biochim. Biophys. Sin. (Shanghai), 2022, 54(3), 378-387. doi: 10.3724/abbs.2022005 PMID: 35538035
  32. Zhou, B.; Guo, W.; Sun, C.; Zhang, B.; Zheng, F. Linc00462 promotes pancreatic cancer invasiveness through the miR-665/TGFBR1-TGFBR2/SMAD2/3 pathway. Cell Death Dis., 2018, 9(6), 706. doi: 10.1038/s41419-018-0724-5 PMID: 29899418
  33. Yang, J.; Antin, P.; Berx, G.; Blanpain, C.; Brabletz, T.; Bronner, M.; Campbell, K.; Cano, A.; Casanova, J.; Christofori, G.; Dedhar, S.; Derynck, R.; Ford, H.L.; Fuxe, J.; García de Herreros, A.; Goodall, G.J.; Hadjantonakis, A.K.; Huang, R.Y.J.; Kalcheim, C.; Kalluri, R.; Kang, Y.; Khew-Goodall, Y.; Levine, H.; Liu, J.; Longmore, G.D.; Mani, S.A.; Massagué, J.; Mayor, R.; McClay, D.; Mostov, K.E.; Newgreen, D.F.; Nieto, M.A.; Puisieux, A.; Runyan, R.; Savagner, P.; Stanger, B.; Stemmler, M.P.; Takahashi, Y.; Takeichi, M.; Theveneau, E.; Thiery, J.P.; Thompson, E.W.; Weinberg, R.A.; Williams, E.D.; Xing, J.; Zhou, B.P.; Sheng, G. Guidelines and definitions for research on epithelial–mesenchymal transition. Nat. Rev. Mol. Cell Biol., 2020, 21(6), 341-352. doi: 10.1038/s41580-020-0237-9 PMID: 32300252
  34. Pastushenko, I.; Blanpain, C. EMT transition states during tumor progression and metastasis. Trends Cell Biol., 2019, 29(3), 212-226. doi: 10.1016/j.tcb.2018.12.001 PMID: 30594349
  35. Mittal, V. Epithelial mesenchymal transition in tumor metastasis. Annu. Rev. Pathol., 2018, 13(1), 395-412. doi: 10.1146/annurev-pathol-020117-043854 PMID: 29414248
  36. Carneiro, B.A.; El-Deiry, W.S. Targeting apoptosis in cancer therapy. Nat. Rev. Clin. Oncol., 2020, 17(7), 395-417. doi: 10.1038/s41571-020-0341-y PMID: 32203277
  37. Mirzaei, S.; Gholami, M.H.; Hushmandi, K.; Hashemi, F.; Zabolian, A.; Canadas, I.; Zarrabi, A.; Nabavi, N.; Aref, A.R.; Crea, F.; Wang, Y.; Ashrafizadeh, M.; Kumar, A.P. The long and short non-coding RNAs modulating EZH2 signaling in cancer. J. Hematol. Oncol., 2022, 15(1), 18. doi: 10.1186/s13045-022-01235-1 PMID: 35236381
  38. Li, Y.; Wan, Q.; Wang, W.; Mai, L.; Sha, L.; Mashrah, M.; Lin, Z.; Pan, C. LncRNA ADAMTS9-AS2 promotes tongue squamous cell carcinoma proliferation, migration and EMT via the miR-600/EZH2 axis. Biomed. Pharmacother., 2019, 112, 108719. doi: 10.1016/j.biopha.2019.108719 PMID: 30970517
  39. Chen, M.J.; Deng, J.; Chen, C.; Hu, W.; Yuan, Y.C.; Xia, Z.K. LncRNA H19 promotes epithelial mesenchymal transition and metastasis of esophageal cancer via STAT3/EZH2 axis. Int. J. Biochem. Cell Biol., 2019, 113, 27-36. doi: 10.1016/j.biocel.2019.05.011 PMID: 31102664

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bentham Science Publishers, 2024